Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience

Patients with advanced esophageal squamous cell carcinoma (SCC) have a poor prognosis when treated with standard chemotherapy. Programmed death ligand 1 (PD-L1) expression in esophageal cancer has been associated with poor survival and more advanced stage. Immune checkpoint inhibitors, such as PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Ming-Wei, Kuo, Yao-Hung, Hsieh, Kun-Chou, Lee, Ching-Tai, Wu, Shih-Chi, Yang, Wen-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139434/
https://www.ncbi.nlm.nih.gov/pubmed/37108474
http://dx.doi.org/10.3390/ijms24087312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139434/
https://www.ncbi.nlm.nih.gov/pubmed/37108474
http://dx.doi.org/10.3390/ijms24087312

Ejemplares similares